Imagine a world where unlocking the secrets of proteins is as easy as running a simple test. A world where every lab, regardless of size or resources, has access to cutting-edge proteomics technology. That's the vision driving Olink, and today, they've announced a major leap forward that could revolutionize disease research.
The core mission at Olink has always been crystal clear: to democratize high-quality proteomics, making it universally accessible. Think of it as leveling the playing field, empowering more scientists to delve into the intricacies of proteins and their role in health and disease.
And the exciting news? Olink® Reveal, their groundbreaking platform, is now officially verified for seamless sequencing on MGI T1+ and G400 sequencers. This verification comes with optimized protocols and confirmed performance, ensuring accuracy and reliability. You can dive deeper into the specifics here: [link to article].
But what does this verification really mean? Essentially, it dramatically expands access to next-generation proteomics. By enabling compatibility with MGI sequencers, more labs can now generate reliable, high-quality protein data using a streamlined, NGS-based workflow. This means researchers can explore disease biology with unprecedented depth, analyzing approximately 1,000 carefully selected proteins known to provide actionable biological insights. Consider, for example, a small research lab studying a rare genetic disorder. Previously, they might have been limited by the cost and complexity of traditional proteomics methods. Now, with Olink® Reveal and MGI sequencers, they can access a powerful toolset to identify key protein biomarkers and potentially uncover new therapeutic targets.
And this is the part most people miss... It's not just about the technology; it's about the impact. This expanded access has the potential to accelerate scientific discovery, leading to earlier diagnoses, more effective treatments, and ultimately, improved patient outcomes. Olink's commitment to making high-quality proteomics accessible to every lab, everywhere, is a testament to their dedication to advancing scientific knowledge and improving human health.
But here's where it gets controversial... Some might argue that focusing solely on NGS-based proteomics could limit the exploration of the full proteome, potentially overlooking important protein interactions and modifications that other techniques might capture. Is this a valid concern, or does the accessibility and scalability of NGS-based proteomics outweigh this potential limitation? What are your thoughts? Share your opinions in the comments below!
Source: Olink®- Part of Thermo Fisher Scientific. (2025, November 13). Bringing accessible NGS-based proteomics to even more labs. News-Medical. Retrieved on November 13, 2025 from https://www.news-medical.net/news/20251113/Bringing-accessible-NGS-based-proteomics-to-even-more-labs.aspx.
Citations
Please use one of the following formats to cite this article in your essay, paper or report:
APA
Olink®- Part of Thermo Fisher Scientific. (2025, November 13). Bringing accessible NGS-based proteomics to even more labs. News-Medical. Retrieved on November 13, 2025 from https://www.news-medical.net/news/20251113/Bringing-accessible-NGS-based-proteomics-to-even-more-labs.aspx.MLA
Olink®- Part of Thermo Fisher Scientific. "Bringing accessible NGS-based proteomics to even more labs". News-Medical. 13 November 2025. https://www.news-medical.net/news/20251113/Bringing-accessible-NGS-based-proteomics-to-even-more-labs.aspx.Chicago
Olink®- Part of Thermo Fisher Scientific. "Bringing accessible NGS-based proteomics to even more labs". News-Medical. https://www.news-medical.net/news/20251113/Bringing-accessible-NGS-based-proteomics-to-even-more-labs.aspx. (accessed November 13, 2025).Harvard
Olink®- Part of Thermo Fisher Scientific. 2025. Bringing accessible NGS-based proteomics to even more labs. News-Medical, viewed 13 November 2025, https://www.news-medical.net/news/20251113/Bringing-accessible-NGS-based-proteomics-to-even-more-labs.aspx.
Terms
While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.
Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.
Please do not ask questions that use sensitive or confidential information.
Read the full Terms & Conditions (https://www.news-medical.net/life-sciences/terms).
